Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Biocept, Inc. BIOC
$0.25
+$0 (1.11%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
4462077.00000000
-
week52high
1.64
-
week52low
0.24
-
Revenue
25858000
-
P/E TTM
0
-
Beta
0.92595100
-
EPS
-1.79000000
-
Last Dividend
0.00000000
-
Next Earnings Date
22 мая 2023 г. в 10:59
Описание компании
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Buy | 25 ноя 2020 г. | |
| H.C. Wainwright | Buy | 25 ноя 2020 г. | |
| Feltl & Co. | Buy | Hold | 25 ноя 2020 г. |
| Chardan Capital | Buy | 25 ноя 2020 г. | |
| Maxim Group | Buy | 26 мар 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| DAO-HADDOCK QUYEN THI | A | 10000 | 10000 | 17 ноя 2022 г. |
| Chandler Marsha Alpert | A | 10000 | 10000 | 08 июл 2022 г. |
| Gerhardt Bruce | A | 10000 | 10000 | 08 июл 2022 г. |
| Rubinstein Linda M | A | 10000 | 10000 | 08 июл 2022 г. |
| ROYSTON IVOR | A | 10000 | 10000 | 08 июл 2022 г. |
| Wilson Margaret Faye | A | 10000 | 10000 | 08 июл 2022 г. |
| Taylor Darrell | A | 15450 | 15450 | 31 мар 2022 г. |
| Marchand Philippe | A | 150000 | 150000 | 31 мар 2022 г. |
| Taylor Darrell | A | 134550 | 134550 | 28 февр 2022 г. |
| Riccitelli Samuel D | A | 250000 | 250000 | 28 февр 2022 г. |
Новостная лента
Biocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial year
Proactive Investors
17 апр 2023 г. в 16:47
Biocept Inc (NASDAQ:BIOC), which develops and commercializes molecular diagnostic assays, revealed new details about its plans to get its CNSide assay system off the ground in 2023. Interim CEO Samuel Riccitelli told shareholders that the company decided that the best course of action is to further develop and commercialize CNSide while pursuing various options to extend its cash runway.
Biocept says enrollment begins in FORESEE clinical trial using CNSide to evaluate patients with leptomeningeal metastases
Proactive Investors
24 мар 2023 г. в 09:01
Biocept Inc (NASDAQ:BIOC), a provider of molecular diagnostic assays, products and services, revealed that the first patient with leptomeningeal metastases has been enrolled in the FORESEE clinical trial with the company's proprietary cerebrospinal fluid assay CNSide (NCT05414123). In a nutshell, leptomeningeal metastases, or LM, is cancer in your cerebrospinal fluid and membranes that surround your brain and spinal cord (the leptomeninges).
Biocept, Inc. (BIOC) Q3 2022 Earnings Call Transcript
Seeking Alpha
28 ноя 2022 г. в 18:26
Biocept, Inc. (NASDAQ:BIOC ) Q3 2022 Earnings Conference Call November 28, 2022 4:00 PM ET Company Participants Jody Cain - LHA Investor Relations Sam Riccitelli - Chairman and Interim President and Chief Executive Officer Antonino Morales - Interim Chief Financial Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Operator Good day, and welcome to the Biocept Third Quarter Financial Results Conference Call. All participants are in a listen-only mode.
Biocept reports 176% year-over-year jump in orders for CNSide assay
Proactive Investors
21 ноя 2022 г. в 16:53
Biocept Inc (NASDAQ:BIOC) has reported a 176% year-over-year jump in orders for its CNSide product, a cerebrospinal fluid assay addressing unmet needs for patients with central nervous system metastasis. Commenting on its third-quarter results, Biocept CEO Samuel Riccitelli said the company was executing well on its strategy to generate further evidence to secure higher reimbursement for CNSide and support its adoption into clinical care guidelines.
Biocept adds CPA Quyen Dao-Haddock to board, bringing extensive financial acumen to audit committee
Proactive Investors
18 ноя 2022 г. в 08:59
Biocept Inc (NASDAQ:BIOC) said it has appointed certified public accountant Quyen Dao-Haddock to its board of directors, bringing her more than 20 years of financial and accounting experience to the audit committee. This increases board membership to eight for the San Diego-based provider of molecular diagnostic assays, products and services.